Up 41% in 2018: Is it too late to buy ResMed Inc shares?

The market may be sinking lower today, but that hasn’t stopped the ResMed Inc. (ASX: RMD) share price from continuing its impressive run.

In afternoon trade the medical device company’s shares are up around 0.5% to $15.23.

This small gain means that ResMed’s shares have stretched their year to date return to almost 41%.

Is it too late to invest?

I don’t believe it is if you are prepared to make a buy and hold investment.

I was very impressed with the company’s performance in the September quarter, which has traditionally been its weakest quarter.

Revenue for the quarter grew by 12% over the prior corresponding period to US$588.3 million and, thanks to the company’s operating leverage continuing to impress, income from operations rose 28% to US$144.1 million.

Management also advised that its growth strategy is being implemented successfully, putting it on target to achieve its long-term goal of changing 20 million lives by 2020.

All in all, I believe this has positioned the company to continue its above-average earnings growth for the foreseeable future, potentially making it a great investment option today.

One broker that agrees is Credit Suisse. A note out of the investment bank today reveals that it has retained its outperform rating and lifted the price target on ResMed’s shares to $16.10 following the acquisition of Propeller Health for US$225 million.

Credit Suisse is pleased that the acquisition provides a data platform for chronic obstructive pulmonary disease, which is something that had been lacking from its portfolio in the past. Another positive is that the broker also expects the acquisition to broaden its customer base.

I agree with this view and think investors ought to consider picking up its shares along with fellow healthcare stars Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL).

5 Companies we like better than ResMed Inc

When ace stock picker Scott Phillips has a buy recommendation, history suggests it can pay to listen.

Scott recently revealed what he believes are the five best ASX stocks for investors to buy right now… and ResMed Inc wasn’t one of them! That’s right — he thinks these 5 stocks are even better buys.

See the 5 stocks

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.